Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who can provide an assent form signed by themselves and informed consent form by their legal representatives prior to performing of any study procedures.~2. Male or female children and adolescents aged 6 to 18 years~3. Patients who are diagnosed with chronic tic disorders(Motor or Phonic) or Tourette's disorder according to DSM-IV(Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition)(using K-SADS-PL-K (Kiddle-Schedule for Affective Disorders and Schizophrenia,Present and Lifetime Version-Korean version)) and require drug therapy.~4. The total tic score of the K-YGTSS (Korean version of Yale Global Tic Severity Scale)is more than 22 at baseline~Exclusion Criteria:~1. Patients with secondary tic symptoms accompanied by Tardive tics, Huntington disease, neuroacanthocytosis, mental retardation, or autism~2. Patients with IQ (Intelligence quotient) (assessed using KEDI-WISC (Korean educational Development Institute-Wechsler Intelligence Scale for children)) 70 and lower than 70~3. Patients with a history of neuroleptic malignant syndrome~4. Patients with antipsychotic or alcohol use disorder (abuse, dependence, and/or withdrawal) according to DSM-IV criteria for the past 3 months~5. Patients with a history of allergy or hypersensitivity reaction to aripiprazole~6. Patients with a history of resistance to treatment with antipsychotics~7. Patients who have participated in another clinical study within 1 month prior to screening~8. Patients who have previously taken aripiprazole or participated in a clinical study with aripiprazole

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
- 2 (Type: PLACEBO_COMPARATOR): Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)

Based on this trial design, predict the completion outcome and termination type (if applicable).